Evidence map›Paper›PMID 41369701›Full record

ReviewClinical and experimental nephrology2026

mRNA-based therapies: current progress and future prospects for treating kidney disease.

Yiyun Song, Hua Su

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yiyun SongDepartment of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Hua SuDepartment of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. dr_suhua@hust.edu.cn.ORCID http://orcid.org/0000-0002-7245-2749

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately, 1.2 million deaths occur each year from chronic kidney disease worldwide. The incidence is increasing and current treatments have limited efficacy. Many patients with kidney disease inevitably end up with kidney replacement therapy. mRNA has revolutionized the world of molecular therapy and spotlighted the attention of the medical community on its potential clinical application. Currently, mRNA-based therapies have started to emerge in the kidney field. In this review, we describe recent advances in renal mRNA-based therapies and discuss future possibilities for using mRNAs to treat kidney diseases.

Indexed as

Genetic TherapyKidney DiseasesRenal Insufficiency, ChronicRNA, MessengerAnimalsHumansRNA, MessengerKidney diseasemRNA-based therapyProtein replacement

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.